PHILADELPHIA, PA, Oct. 17 /PRNewswire-FirstCall/ - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, announced today that it has established its first central lab in the United States. The new 15,000 square-foot facility, located in North Brunswick, New Jersey is now fully operational, expanding MDS Pharma Services capabilities in late stage pharmaceutical testing. It provides central lab support services for clinical trials.
In addition to standard safety testing, this facility provides esoteric testing including molecular biology, molecular genetics, flow cytometry, and immunoassays. These complex tests are being used increasingly in the drug development industry in the evaluation of targeted treatments for conditions such as cancer, autoimmune diseases, diabetes, and immune deficiencies.
“We established this lab to meet the growing demand from clients for a facility in the United States that offers both standard and complex testing to support the development of new treatments,” said MDS Pharma Services President David Spaight. “This location is easily accessible to many pharmaceutical companies headquartered in the Northeastern United States. It can accommodate clients who conduct clinical trials in and outside the country.”
This new central lab has received accreditation from the College of American Pathologists (CAP), a gold standard in the industry. It has also received a Level 1 certification from the National Glycohemoglobin Standardization Program for providing the highest levels of technical precision and accuracy in standard diabetic testing. This test - commonly referred to as HbA1c - is used to assess a diabetic’s overall wellbeing and to monitor the effectiveness of diabetic treatments.
MDS Pharma Services began offering central lab clinical trial testing services nearly 20 years ago by establishing a central lab in Toronto. Since then, clinical trial testing has become increasingly more complex and global. Today, MDS Pharma Services has grown to become the third largest supplier of central lab clinical trial testing services through its global network of central labs. This network provides global central laboratory and centralized cardiac safety services for clinical trials from MDS facilities in the United States, Canada, Germany, France, Singapore, and China as well as affiliate labs in Argentina, Brazil, and Mexico.
About MDS Pharma Services
MDS Pharma Services offers a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, the company applies advanced scientific and technological expertise to each stage of the drug discovery and development process - Early Stage: lead optimization, pre-IND research, pharmaceutical and biopharmaceutical development, early clinical research (bioequivalence, phases I-IIa) and bioanalysis; and Late Stage: global clinical development (phases IIb-IV) and central lab. For more information, visit MDS Pharma Services’ Web site at www.mdsps.com.
MDS Pharma Services is an integral part of MDS Inc. . MDS Inc. has more than 8,800 highly skilled people in 28 countries. It provides a diverse range of superior products and services to increase customers’ speed, precision and productivity in the drug development and disease diagnosis processes. MDS is a global, values-driven life sciences company, recognized for its reliability and collaborative relationships that help create better outcomes in the treatment of disease. Find out more at www.mdsinc.com or by calling 1-800-MDS-7222, 24 hours a day.
MDS Pharma Services
CONTACT: For Investors: Sharon Mathers, (416) 675-6777 ext. 4721,Sharon.Mathers@mdsinc.com; For Media: Charlene McGrady, (610) 239-7900,ext. 231, Charlene.Mcgrady@mdsps.com
